Remove Biosimilars Remove Compounding Remove Process Improvement
article thumbnail

NHC Submits Comments on CMS Draft Guidance for IPAY 2028

Putting Patients First Blog

At the same time, the NHC recommends that CMS avoid incorporating the MFP into ASP calculations, as doing so could depress reimbursement rates across both Medicare and commercial markets, compounding access risks and straining provider viability. A first priority is clarifying how providers should submit claims for drugs subject to the MFP.

article thumbnail

The next frontier: Global leadership in biopharma

Express Pharma

Sasmitha Sahu, Managing Consultant, GlobalData states, “While India has demonstrated success in generic drug production, the same is not true for novel and biosimilar biopharma products.” These trends serve as crucial catalysts, necessitating a shift in priorities and a much-needed transformation of the manufacturing sector.”